tacrolimus and 2-5-di-tert-butylhydroquinone

tacrolimus has been researched along with 2-5-di-tert-butylhydroquinone* in 2 studies

Other Studies

2 other study(ies) available for tacrolimus and 2-5-di-tert-butylhydroquinone

ArticleYear
Ca2+-ATPase inhibitors and PKC activation synergistically stimulate TNF-alpha production in RBL-2H3 cells.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 1998, Volume: 47, Issue:8

    To investigate the effect of Ca2+-ATPase inhibitors on the production of TNF-alpha in rat basophilic leukemia (RBL-2H3) cells.. Two Ca2+-ATPase inhibitors, thapsigargin (TG) and cyclopiazonic acid (CPA), and three hydroquinone-antioxidants, 2,5-di-(tert-butyl)-1,4-hydroquinone (DTBHQ), 2,5-di-(tert/amyl)-1,4-hydroquinone (DTAHQ), 2-(tertbutyl)-1,4-hydroquinone (MTBHQ) were used.. Cells were treated with TG, CPA, DTBHQ, DTAHQ and MTBHQ for 3 h in the presence of 12-Otetradecanoylphorbol-13-acetate (TPA) and released TNF-alpha from the cells was measured (n > or = 4).. All Ca2--ATPase inhibitors (TG, CPA, DTBHQ and DTAHQ) induced TNF-alpha release in a dose-dependent manner. TNF-alpha release was inhibited by treatment with protein kinase C inhibitors (staurosporine, Ro31-8220, calophostin C) (p < or = 0.05). In contrast, MTBHQ, which does not induce increases in [Ca2+]i, did not induce the release of TNF-alpha. TNF-alpha release induced by DTBHQ and CPA was inhibited by treatment with actinomycin-D, the immunosuppressant FK506 and the glucocorticoid dexamethasone (p < or = 0.01).. These results suggest 1) that [Ca2+]i increase and subsequent activation of protein kinase C is necessary for the release of TNF-alpha, and they work synergistically, 2) that the TNF-alpha release induced by Ca2+-ATPase inhibitors can be regulated at the transcriptional level.

    Topics: Animals; Calcium-Transporting ATPases; Dactinomycin; Dexamethasone; Enzyme Activation; Enzyme Inhibitors; Hydroquinones; Indoles; Leukemia, Basophilic, Acute; Protein Kinase C; Rats; Tacrolimus; Thapsigargin; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

1998
Ca2+-ATPase inhibitor induces IL-4 and MCP-1 production in RBL-2H3 cells.
    Immunology letters, 1998, Volume: 64, Issue:1

    The effects of a Ca2(+)-ATPase inhibitor, cyclopiazonic acid (CPA), and two hydroquinone-antioxidants, 2,5-di-(tert-butyl)-1,4-hydroquinone (DTBHQ) and 2,5-di-(tert-amyl)-1,4-hydroquinone (DTAHQ) on the release of IL-4 and MCP-1 from RBL-2H3 cells were investigated. CPA, DTBHQ and DTAHQ, all of which induce intracellular free Ca2+ concentration ([Ca2+]i) increase, induced IL-4 and MCP-1 release in a dose-dependent manner. The release of TNF-alpha required both a Ca2(+)-ATPase inhibitor and 12-O-tetradecanoylphorbol-13-acetate (TPA). However, the Ca2(+)-ATPase inhibitors induced IL-4 and MCP-1 production without TPA. The release of IL-4 and MCP-1 reached a maximum at 9 and 6 h, respectively. IL-4 and MCP-I release was inhibited by treatment with the immunosuppressant FK-506 and actinomycin D. Therefore, in our system IL-4 and MCP-1 release involves Ca2(+)-dependent and FK-506-sensitive signaling pathways. This is the first report about Th-2 type cytokine and chemokine production in RBL-2H3 cells.

    Topics: Animals; Antioxidants; Calcium-Transporting ATPases; Chemokine CCL2; Dactinomycin; Dose-Response Relationship, Drug; Hydroquinones; Indoles; Interleukin-4; Mast Cells; Rats; Tacrolimus; Tetradecanoylphorbol Acetate; Time Factors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

1998